Callitas Health Inc. Stock Analysis MPHMF

Callitas Health, Inc. is a clinical stage company. The company is headquartered in Newport, Kentucky. The company went IPO on 2008-05-20. The firm is focused on developing technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. Its pharmaceutical/research and development pipeline includes C-103, which is a reformulation of Xenical (Orlistat 120 mg) for the treatment of obesity which minimizes adverse side effects associated with the use of Xenical, and Extrinsa, is a topical prescription gel that increases vaginal blood flow addressing female sexual dysfunction (FSD) issues. Extrinsa uses a combination of menthol/L-arginine and tadalafil (a PD5 inhibitor).